Grandfield & Dodd LLC Decreases Holdings in AstraZeneca PLC (NASDAQ:AZN)

Grandfield & Dodd LLC trimmed its position in AstraZeneca PLC (NASDAQ:AZN) by 16.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,426 shares of the company’s stock after selling 1,455 shares during the period. Grandfield & Dodd LLC’s holdings in AstraZeneca were worth $579,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. McClarren Financial Advisors Inc. increased its position in AstraZeneca by 320.8% during the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after buying an additional 247 shares in the last quarter. GHP Investment Advisors Inc. purchased a new stake in shares of AstraZeneca during the second quarter worth about $26,000. Capital Performance Advisors LLP acquired a new position in shares of AstraZeneca during the third quarter valued at about $28,000. Pathway Financial Advisers LLC purchased a new position in shares of AstraZeneca in the 1st quarter valued at approximately $29,000. Finally, CANADA LIFE ASSURANCE Co boosted its stake in AstraZeneca by 40.6% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock worth $34,000 after purchasing an additional 146 shares in the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on AZN. TD Cowen upped their price target on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Monday, August 12th. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Finally, Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $89.75.

AstraZeneca Trading Up 0.6 %

Shares of NASDAQ AZN opened at $63.80 on Wednesday. The stock has a fifty day simple moving average of $74.34 and a 200-day simple moving average of $78.06. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $197.82 billion, a PE ratio of 30.53, a PEG ratio of 1.17 and a beta of 0.47.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.01 by $0.03. The business had revenue of $13.57 billion during the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business’s revenue for the quarter was up 18.0% compared to the same quarter last year. During the same quarter last year, the firm posted $0.87 earnings per share. On average, equities analysts forecast that AstraZeneca PLC will post 4.07 earnings per share for the current year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.